Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects

Payne Christopher D.; Deeg Mark A.; Chan Melanie; Tan Lai Hock; LaBell Elizabeth Smith; Shen Tong; DeBrota David J.

首页> 外文期刊>British Journal of Clinical Pharmacology >Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects

【24h】

Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects

机译：组织蛋白酶S抑制剂LY3000328在健康受试者中的药代动力学和药效学

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

AimThe aim of this study was to assess the safety and tolerability, pharmacokinetics and pharmacodynamics of LY3000328 when administered as single escalating doses to healthy volunteers.

机译：目的本研究旨在评估以单次递增剂量向健康志愿者施用LY3000328的安全性和耐受性，药代动力学和药效学。

著录项

来源
《British Journal of Clinical Pharmacology》 |2014年第6期|共9页
作者
Payne Christopher D.; Deeg Mark A.; Chan Melanie; Tan Lai Hock; LaBell Elizabeth Smith; Shen Tong; DeBrota David J.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词
cathepsin S inhibitor; LY3000328;

机译：组织蛋白酶S抑制剂;LY3000328;
入库时间 2022-08-18 09:14:20

相似文献

外文文献
中文文献
专利

1. Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects [J] . Payne Christopher D., Deeg Mark A., Chan Melanie, British Journal of Clinical Pharmacology . 2014,第6期

机译：组织蛋白酶S抑制剂LY3000328在健康受试者中的药代动力学和药效学
2. Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-o-methyltransferase inhibitor, in healthy subjects : prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor. [J] . Luis Almeida, José Francisco Rocha, Amílcar Falc?o, Clinical pharmacokinetics . 2013,第2期

机译：新型儿茶酚-o-甲基转移酶抑制剂奥皮卡酮的药代动力学，药效学和耐受性：在健康受试者中：短期和非常长效抑制剂的慢酶抑制剂复合物解离的预测。
3. Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: Safety, tolerability, pharmacokinetics and pharmacodynamics - results from single oral dose studies in healthy volunteers [J] . StochS.A., ZajicS., StoneJ.A., British Journal of Clinical Pharmacology . 2013,第5期

机译：Odanacatib，一种选择性的组织蛋白酶K抑制剂，可治疗骨质疏松症：安全性，耐受性，药代动力学和药效学-来自健康志愿者的单次口服剂量研究结果
4. Interaction of subcutaneous lixisenatide 20 μg QD on pharmacokinetic and pharmacodynamic properties of oral ramipril 5 mg QD in steady state in young healthy males and females [C] . Dahmen R, Steinstraesser A, Poitiers F, European Association for Clinical Pharmacology and Therapeutics . 2011

机译：皮下丽西齐肽的相互作用20μgQD对年轻健康男性稳态口腔ramipril 5mg qd的药代动力学和药物动力学性质
5. Pharmacokinetic/Pharmacodynamic Analyses of Avatrombopag in Healthy Subjects and Patients with Chronic Liver Disease [D] . NOMOTO, Maiko 2019

机译：阿法曲巴帕在健康受试者和慢性肝病患者中的药代动力学/药效学分析
6. Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor LY3000328 in healthy subjects [O] . Christopher D Payne, Mark A Deeg, Melanie Chan, 2014

机译：组织蛋白酶S抑制剂LY3000328在健康受试者中的药代动力学和药效学
7. Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics: results from single oral dose studies in healthy volunteers [O] . Stoch, S Aubrey, Zajic, Stefan, Stone, Julie A, 2013

机译：Odanacatib，一种治疗骨质疏松症的选择性组织蛋白酶K抑制剂：安全性，耐受性，药代动力学和药效学：健康志愿者单次口服剂量研究的结果

Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects

摘要

著录项

相似文献

相关主题

期刊订阅